Senior Accountant, AbCellera Biologics
CA$73.5-91.9k
+ Equity and annual bonus
Biotech focused on antibody treatments
Open for applications
Biotech focused on antibody treatments
501-1000 employees
Open for applications
CA$73.5-91.9k
+ Equity and annual bonus
501-1000 employees
Company mission
To improve health with technologies that transform the way that antibody-based therapies are discovered.
Role
Who you are
- You have a minimum of 5 years’ work experience in a similar role or a CPA and/or equivalent designation
- You are proficient in using Excel and Google Sheets
- You are a team player who enjoys working in a dynamic, fast-paced environment
- You have impeccable attention to detail
- You are able to work independently, and demonstrate initiative and accountability
- You think critically and show great judgment in your decision-making process
What the job involves
- We are seeking a highly-motivated and adaptable Senior Accountant to join our Finance team and contribute to building a Company on a strong foundation of financial processes and workflows to support the mission
- Contributing to preparing AbCellera’s financial records in compliance with company policies and US GAAP
- Assisting in month-end, quarter-end, and year-end closing processes by preparing detailed financial reports and schedules related to fixed assets, leases, indirect tax compliance, and supporting other close activities
- Participating in the maintenance of internal accounting controls as they relate to overall financial reporting in compliance with SOX regulations
- Managing the fixed asset register by collaborating with cross-functional teams to support accurate recording of fixed asset additions, transfers, disposals, and maintenance of amortization schedules
- Assisting with internal and external auditor requests for period end reporting requirements
- Collaborating with special projects, transactions, and general operations where necessary
- Providing general support to your Finance teammates as needed
Our take
The increasing application of artificial intelligence in pharmaceutical contexts combined with the declining capabilities of antibiotic treatment has opened up a huge opportunity for antibody-discovery firm, AbCellera.
The company provides an artificial-intelligence powered platform for identifying antibodies and developing treatments, and it scored a big win by helping Eli Lilly identify the antibody for its bamlanivimab COVID treatment.
The company is looking to successfully execute its 100 or so discovery programs for new drugs from which it can hope to earn millions in royalties.
The challenge for AbCellera, like many startups in the space, will be staying ahead of the curve in the application of emerging technologies while maintaining total compliance with regulations. So far signs are encouraging : it saw its revenues increase by about 25% over 2022 as it added 18 new partnerships in the period.
Steph
Company Specialist at Welcome to the Jungle
Insights
35% employee growth in 12 months
Company
Funding (last 2 of 8 rounds)
May 2023
$497.3m
GRANT
May 2020
$102.2m
SERIES B
Total funding: $618.1m
Company benefits
- Health Benefits - Stay well with a comprehensive health benefits package that includes health, dental, life and critical illness coverage
- Stock Options - Work together, win together with an ownership stake in AbCellera.
- Active Lifestyle Allowance - Use the active lifestyle allowance for the fitness activities that keep you active and healthy
- Paid Vacation - You work hard and should take well-deserved time off, starting with a minimum of 3 weeks' vacation
- Flexible Work Hours - Optimize how you work with flexible work hours.
- Personal & Professional Development - Ignite your curiosity, learn and be inspired through workshops, conferences and programs
- Work-Life Balance - Take the time you need to support yourself and your family.
- Immigration & Relocation Assistance - Get you (and your family) settled into a new city with the help of our team, including personalized immigration support
Company HQ
Mount Pleasant, Vancouver, BC
Leadership
Carl Hansen
(CEO)Until August 2019, Carl was a Professor at the University of British Columbia, where they co-authored over 65 papers in the fields of microfluidics, immunology, genomics, and nanotechnology. Before leading AbCellera, they were a scientific Co-Founder of Precision Nanosystems, and served on the SAB of Fluidigm Corp.
Véronique Lecault
(COO)Véronique received their PhD in Chemical and Biological Engineering from the University of British Columbia, where they co-invented the high-throughput microfluidic platform that is now part of AbCellera’s core technology. They are a recipient of the L’Oreal-UNESCO For Women in Science Mentorship Award.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 1 more job at AbCellera Biologics